<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220165</url>
  </required_header>
  <id_info>
    <org_study_id>MGL-3196-07</org_study_id>
    <nct_id>NCT03220165</nct_id>
  </id_info>
  <brief_title>Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196</brief_title>
  <official_title>An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Madrigal Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Madrigal Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a&#xD;
      radio-labeled version of MGL-3196.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2017</start_date>
  <completion_date type="Actual">September 3, 2017</completion_date>
  <primary_completion_date type="Actual">September 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance of [14C] MGL-3196</measure>
    <time_frame>Approximately 10 Days</time_frame>
    <description>Measurement of the total radioactivity collected from blood, urine, and feces</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGL-3196</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGL-3196</intervention_name>
    <description>oral, 100 mg</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>VIA-3196</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily consents to participate and provides written informed consent.&#xD;
&#xD;
          -  Is a male.&#xD;
&#xD;
          -  Is between 18 and 55 years of age (inclusive).&#xD;
&#xD;
          -  Has a body mass index (BMI) between 18 and 32 kg/m2 (inclusive), and weighs a minimum&#xD;
             of 50 kg.&#xD;
&#xD;
          -  Is willing and able to remain in the study unit for the entire duration of the&#xD;
             confinement periods&#xD;
&#xD;
          -  Is willing to eat entire meals and snacks provided during confinement at the research&#xD;
             facility; and understand that the diet will include foods with high fiber content and&#xD;
             possibly prune juice.&#xD;
&#xD;
          -  Is willing to have collected all urine and fecal samples for the duration of the study&#xD;
             period as required.&#xD;
&#xD;
          -  Is willing to use a waterless commode located in a designated dry room for urine and&#xD;
             feces collection for the duration of the study period as required.&#xD;
&#xD;
          -  Is willing to abstain from showering for the first 72 hours after administration of&#xD;
             [14C] MGL-3196. After the restriction from showering is lifted, must be willing to&#xD;
             provide a urine sample prior to showering for the remainder of the confinement period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, oncologic, or psychiatric disease or any other condition that, in the&#xD;
             opinion of the Investigator, would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
&#xD;
          -  A clinically significant abnormal finding on the physical exam, medical history,&#xD;
             electrocardiogram (ECG), or clinical laboratory results at screening.&#xD;
&#xD;
          -  Thyroid stimulating hormone test at screening outside the normal range. Repeat testing&#xD;
             is allowed once at the discretion of the Investigator.&#xD;
&#xD;
          -  Current or recent (&lt;6 months) hepatobiliary disease; or AST, ALT or direct bilirubin&#xD;
             greater than the upper limit of reference range at screening. Repeat testing is&#xD;
             allowed once at the discretion of the Investigator.&#xD;
&#xD;
          -  Elevated CK at screening (one repeat test allowed).&#xD;
&#xD;
          -  History of Gilbert's syndrome.&#xD;
&#xD;
          -  Pre-existing condition interfering with normal gastrointestinal anatomy or motility,&#xD;
             hepatic and/or renal function that could interfere with the absorption, metabolism,&#xD;
             and/or excretion of the study drug.&#xD;
&#xD;
          -  Abnormal screening ECG: including machine-read QTcF &gt;450 msec (confirmed by manual&#xD;
             over read), QRS &gt;110 msec, intermittent bundle branch block, frequent premature atrial&#xD;
             or premature ventricular contractions, or any rhythm other than normal sinus rhythm&#xD;
             which is interpreted by the Investigator to be clinically significant.&#xD;
&#xD;
          -  History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis&#xD;
             MB7811), or a history of important drug or other allergy (except for untreated,&#xD;
             asymptomatic seasonal allergies at time of dosing) unless deemed not clinically&#xD;
             significant by the Investigator.&#xD;
&#xD;
          -  History of sensitivity to thyroid medication.&#xD;
&#xD;
          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose&#xD;
             of study medication.&#xD;
&#xD;
          -  Has participated in a standard radiolabeled clinical trial within the last 12 months&#xD;
             prior to the first dose of study medication or a micro tracer clinical trial within&#xD;
             the last 3 months prior to the first dose of study medication.&#xD;
&#xD;
          -  Has participated in another clinical trial (randomized subjects only) within 30 days&#xD;
             prior to the first dose of study medication.&#xD;
&#xD;
          -  Use of any over-the-counter (OTC) medication (including nutritional or dietary&#xD;
             supplements, herbal preparations, vitamins, or acetaminophen) within 7 days prior to&#xD;
             the first dose of study medication until the end of study visit without evaluation and&#xD;
             approval by the Investigator.&#xD;
&#xD;
          -  Use of any prescription medication from 14 days prior to the first dose of study&#xD;
             medication until the end-of-study visit without evaluation and approval by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Has been treated with any known drugs that are moderate or strong inhibitors/inducers&#xD;
             of cytochrome P450 (CYP) enzymes (e.g., barbiturates, phenothiazines, cimetidine,&#xD;
             carbamazepine) within 30 days prior to the first dose of study medication, and that,&#xD;
             in the Investigator's judgment, may impact subject safety or the validity of the study&#xD;
             results.&#xD;
&#xD;
          -  Blood or plasma donation within 30 days prior to the first dose of study medication&#xD;
             until the end-of-study visit. It is recommended that blood/plasma donations not be&#xD;
             made for at least 30 days after the end-of-study visit.&#xD;
&#xD;
          -  Smoking or use of tobacco- or nicotine-containing products within 60 days prior to the&#xD;
             first dose of study medication until the end-of-study visit.&#xD;
&#xD;
          -  Consumption of beverages or foods that contain grapefruit, poppy seeds, broccoli,&#xD;
             Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine&#xD;
             from 48 hours prior to the first dose of study medication until the end-of-study&#xD;
             visit. Subjects will be instructed not to consume any of the above products; however,&#xD;
             allowance for an isolated single incidental consumption may be evaluated and approved&#xD;
             by the study Investigator based on the potential for interaction with the study drug.&#xD;
&#xD;
          -  Has any prior history of substance abuse or treatment (including alcohol).&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces of&#xD;
             wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Use of alcohol within 24 hours prior to dosing and throughout the study.&#xD;
&#xD;
          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cocaine, cannabinoids, opiates) or cotinine.&#xD;
&#xD;
          -  Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human&#xD;
             immunodeficiency virus (HIV) at screening or has been previously treated for hepatitis&#xD;
             B, hepatitis C, or HIV infection.&#xD;
&#xD;
          -  Excessive caffeine intake (&gt;3 cups of coffee/day or equivalent).&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical disease (e.g., infectious disease) must&#xD;
             not be enrolled.&#xD;
&#xD;
          -  Any other sound medical, psychiatric, and /or social reason as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Has irregular bowel habits. (&quot;Irregular&quot; being defined for the purpose of this study&#xD;
             as NOT having a bowel movement at least every 2 days.)&#xD;
&#xD;
          -  Has been exposed to radiation, including dental or medical imaging such as X-ray or&#xD;
             tomography, in the 6 months prior to dose administration.&#xD;
&#xD;
          -  Has been involved in an occupation that requires monitoring for radiation exposure&#xD;
             (eg, X-ray technician).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Ate, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

